Ramakanta Panda

More People Are Now Eligible for Weight Loss Surgery in St. Louis

Retrieved on: 
Tuesday, January 3, 2023
Bariatric surgery, Body mass index, ASMBS, Bariatrics, Ramakanta Panda, News, BMI, Patient, Type, Exercise, Safety, Type 2 diabetes, Diet, Weight loss, Health, Hypertension, Obesity, Society, Metabolism, Dentistry, Cosmetics, Medical device

The American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) released new evidence-based clinical guidelines that include expanded eligibility for bariatric surgery—meaning more people now qualify for weight loss procedures.

Key Points: 
  • The American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) released new evidence-based clinical guidelines that include expanded eligibility for bariatric surgery—meaning more people now qualify for weight loss procedures.
  • The groups also shared positive news about the effectiveness and safety of weight loss procedures.
  • The BMI requirement is further decreased for individuals of Asian descent, with weight loss surgery considered for people with a BMI above 27.5 regardless of comorbidities.
  • St. Louis Bariatrics , the locally owned weight loss practice led by Dr.

AltrixBio Announces Appointment of John L Brooks III to Corporate Board of Directors as Independent Member

Retrieved on: 
Wednesday, December 14, 2022
Prediabetes, GI, T2D, Brigham and Women's Hospital, Type 2, Patient, Burnet v. Sanford & Brooks Co., Type 2 diabetes, Research, Epidemic, Joslin Diabetes Center, Diabetes, Obesity, Quality of life, Ramakanta Panda, Hospital, Luci, Harvard Medical School, Health, Patent, Brooks, Pharmaceutical industry, Metabolism

CAMBRIDGE, Mass., Dec. 14, 2022 /PRNewswire/ -- AltrixBio, a leading early-stage biotech startup, today announced that John L Brooks III  will join the company's corporate Board of Directors as an independent member.

Key Points: 
  • Diabetes Expert Has Extensive Healthcare Board and Advisor Experience, Helping AltrixBio Bring Patented GI Targeting Solution to market
    CAMBRIDGE, Mass., Dec. 14, 2022 /PRNewswire/ -- AltrixBio , a leading early-stage biotech startup, today announced that John L Brooks III will join the company's corporate Board of Directors as an independent member.
  • Brooks brings over three decades of experience working with early-stage life sciences companies developing innovative solutions to obesity, pre-diabetes, and diabetes.
  • Brooks served as the President and CEO of the Joslin Diabetes Center, the world's preeminent diabetes research, clinical care, and education organization.
  • "We are thrilled to have John Brooks join our Corporate Board as an independent member," said Nancy Briefs, the CEO of AltrixBio.

Medical Simulation Global Market to Reach $4.1 Billion by 2027 at a CAGR of 13.68%

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Environment, Hospital, Artificial intelligence, Patient safety, Appendectomy, Physician, Virtual reality, Ramakanta Panda, Nursing, Hysterectomy, Cholecystectomy, Robotics, Surgeon, Feedback, Augmented reality, AR, Co-production (public services), Medical device, Growth

The global medical simulation market size reached US$ 1.9 Billion in 2021.

Key Points: 
  • The global medical simulation market size reached US$ 1.9 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 4.1 Billion by 2027, exhibiting a CAGR of 13.68% during 2021-2027.
  • Medical simulation uses body manikins, task trainers and virtual reality (VR)-based systems for laparoscopic, gynecological, cardiovascular, arthroscopic, spinal, endovascular, dental and eye simulation.
  • The publisher provides an analysis of the key trends in each sub-segment of the global medical simulation market report, along with forecasts at the global, regional and country level from 2022-2027.

Medical Simulation Global Market Report 2022: Increasing Awareness of the Benefits of Simulation-Based Medical Learning Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
General Health, Radiology, Oncology, Training, Other Education, Hospitals, Health Technology, Education, Surgery, Nursing, Practice Management, Health, COVID-19, Environment, Hospital, Artificial intelligence, Patient safety, Appendectomy, Physician, Virtual reality, Ramakanta Panda, Nursing, Hysterectomy, Cholecystectomy, Robotics, Surgeon, Feedback, Augmented reality, AR, Co-production (public services), Medical device, Growth

The "Medical Simulation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Simulation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global medical simulation market size reached US$ 1.9 Billion in 2021.
  • Moreover, the increasing awareness regarding the benefits of simulation-based learning among the masses is providing a thrust to the market growth.
  • The publisher provides an analysis of the key trends in each sub-segment of the global medical simulation market report, along with forecasts at the global, regional and country level from 2022-2027.

ReShape Lifesciences Announces $750,000 Registered Direct Offering

Retrieved on: 
Tuesday, November 8, 2022
SAN, GLOBE, Private Securities Litigation Reform Act, Act, Park Avenue, U.S. Securities and Exchange Commission, Type 2, Proposal, Nasdaq, Telephone, Anatomy, Sale, Form S-3, Stomach, Prospectus, Person, Securities Act of 1933, Regulation D, SEC, Obesity, Ramakanta Panda, Annual report, Form, Collection, Type 2 diabetes, Weight loss, Venture round, Company, Reshaping Cultural Policies, Patient, Security (finance), FDA

Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is expected to be approximately $750,000.

Key Points: 
  • Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is expected to be approximately $750,000.
  • A final prospectus supplement and accompanying prospectus relating to the securities being offered in the registered direct offering will be filed with the SEC.
  • ReShape Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease.
  • These forward-looking statements and factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering.

ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

Retrieved on: 
Monday, November 7, 2022
SAN, GLOBE, Nasdaq, Obesity, Bus Reshaping Plan, Ramakanta Panda, Patient, Collection, Anatomy, Weight loss, Stomach, FDA, Pharmaceutical industry

A live webcast will be available on the Events and Presentations section of ReShapes website at: https://ir.reshapelifesciences.com/events-and-presentations .

Key Points: 
  • A live webcast will be available on the Events and Presentations section of ReShapes website at: https://ir.reshapelifesciences.com/events-and-presentations .
  • To access the call by phone, please register with the following Registration Link , and dial-in details will be provided.
  • Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.
  • The recently launched ReShape Marketplace is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.

ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®

Retrieved on: 
Thursday, November 3, 2022
Glucose, Private Securities Litigation Reform Act, Diet, Type 2 diabetes, Alloxan, Weight loss, SAN, CA, Obesity, PG, Risk, Industry, GLOBE, Vagotomy, SBIR, Ramakanta Panda, FDA, Safety, Metabolic disorder, Patient, Nasdaq, Plasma, Oxidative stress, Marketing, Roy Taylor (scientist), Research, Vagus nerve, Type 2, Anatomy, Collection, Annual report, U.S. Securities and Exchange Commission, Insulin, Stomach, Pancreas, Diabetes, Forward-looking statement, Reshaping Cultural Policies, CV, Liver, Technology, Security (finance), NIH, Hypoglycemia, SD, Insulin resistance, Ligation, Person, Miniature pig, Pharmaceutical industry, Medical device, T2DM

Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.

Key Points: 
  • Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.
  • Previously, the area under the curve of oral glucose tolerance tests (OGTTs) was calculated to quantify glycemic control.
  • The opportunity to present such compelling data on our proprietary DBSN device at this industry conference is a testament to the market potential of the technology to treat type 2 diabetes, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders.

ReShape Lifesciences to Present at the Q4 Investor Summit

Retrieved on: 
Wednesday, November 2, 2022
Weight loss, Complimentary, Anatomy, GLOBE, Obesity, Nasdaq, Person, Ramakanta Panda, Collection, Type 2, Type 2 diabetes, Bus Reshaping Plan, FDA, Patient, Assam Global Investors' Summit, SAN, Stomach, Pharmaceutical industry

During the presentation, management will highlight its next-generation, anatomy-sparing, Lap-Band program and the nationwide, reshapecare virtual health coaching program.

Key Points: 
  • During the presentation, management will highlight its next-generation, anatomy-sparing, Lap-Band program and the nationwide, reshapecare virtual health coaching program.
  • ReShape Lifesciences management team will be available for one-on-one meetings during the Investor Summit.
  • A live webcast of the Investor Summit presentation will be available on the Events and Presentations section of ReShapes website at: https://ir.reshapelifesciences.com/events-and-presentations .
  • ReShape Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease.

ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

Retrieved on: 
Monday, October 31, 2022
Consensus, Reshaping Cultural Policies, National, Bariatric surgery, U.S. Securities and Exchange Commission, Leadership, Marketing, BMI, Collection, Obesity, Time, Annual report, Private Securities Litigation Reform Act, SAN, Forward-looking statement, Person, Patient, Society, IFSO, Regulation of tobacco by the U.S. Food and Drug Administration, Type 2, Metabolism, Ramakanta Panda, Adult, Security (finance), Anatomy, GLOBE, Type 2 diabetes, FDA, Weight loss, Population, NIH, FACS, Risk, Nasdaq, Stomach, ASMBS, Pharmaceutical industry, Medical device

SAN CLEMENTE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) have issued updated guidelines for Metabolic and Bariatric Surgery, including the Lap-Band®, replacing the 30 year old guidelines issued by the National Institutes of Health (NIH) in 1991.

Key Points: 
  • The full text of the guidelines can be accessed via the following link https://www.soard.org/article/S1550-7289(22)00641-4/fulltext .
  • Metabolic and bariatric surgery, is currently the most effective evidence-based treatment for obesity across all BMI classes.
  • We applaud the leadership of these two industry-leading societies, working together to update these guidelines for bariatric surgery.
  • ReShape Lifesciences is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease.

ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience

Retrieved on: 
Tuesday, October 25, 2022
U.S. Securities and Exchange Commission, SBIR, Lists of diseases, Human, Fasting, Reshaping Cultural Policies, Collection, Private Securities Litigation Reform Act, Myocardial infarction, GLOBE, Frontiers, Pancreas, Type 2 diabetes, Plasma, Annual report, Insulin, Marketing, Diabetes, Adjustable gastric band, Miniature pig, Ligation, Disease, Forward-looking statement, Technology, FDA, Patient, Obesity, University, Vagus nerve stimulation, Vagus nerve, Liver, RATS, Nasdaq, Hypoglycemia, Stomach, Research, Anatomy, Risk, Blood, Stroke, Insulin resistance, Ramakanta Panda, Tuskegee Veterans Administration Medical Center, Weight loss, Security (finance), Pharmaceutical industry, Medical device, Alloxan, Neuroscience, Endocrinology, Medicine

SAN CLEMENTE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that data on the Company’s proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system has been published in the Neural Technology Section of the peer reviewed journal Frontiers in NeuroScience.

Key Points: 
  • When this translates to humans and clinical use, it may greatly impact the standard of care for type 2 diabetes.
  • This study specifically tested the ability of the system to increase glycemic control in a rat model of type 2 diabetes and Alloxan treated swine.
  • Based on the data generated, the study concluded that our proprietary DBSN system may be an adjustable and localized approach for treating type 2 diabetes.
  • The DBSN system utilizes a proprietary, reversable and adjustable electrical blockade felt to be key to the future of personalized medicine.